InvestorsHub Logo
icon url

leifsmith

05/18/14 6:09 PM

#19018 RE: ohibbs #19014

Thanks for this. Somehow I didn't see it. :-)
icon url

leifsmith

05/18/14 6:10 PM

#19019 RE: ohibbs #19014

The word "powerful" was used because of what I have personally observed with friends using Anatabloc (not in all cases, but in enough to be impressive).
icon url

haysaw

05/18/14 9:45 PM

#19020 RE: ohibbs #19014

To state that anatabloc is one of the "most powerful anti-inflammatories ever found" is baseless. There is no credible clinical evidence to suggest this. Are there less credible studies that show anti-inflammatory benefit? Yes, it appears there are. It appears, through these less rigorous studies, to regulate inflammation. That is positive. But does that make it one of the "most powerful" ever found? Hardly.

If you took all the developed drugs (NSAID's, steroids, statins, TNF inhibitors), and all the natural known anti-inflammatories (turmeric, cayenne pepper, pomegranate, marijuana, ginger, garlic, green tea, etc.), and ran parallel studies to compare anti-inflammatory effects, and anatabine came out ahead of the pack or in the top tier, then I could get behind an ambitious statement like that.

Because of the grandiosity of that statement, and the lack of comparable evidence, I'm inclined to think it is arrogant and baseless, respectively. Call it a personal attack if you wish (administrators), but I'll call it common sense.

As far as the safety profile...so far so good. Fwiw, tobacco had a good safety profile for many decades also. I think, however, that because it (anatabine) has been in the food chain for awhile -- without any serious adverse reactions that we know of -- it probably will maintain a good profile. Part of this is probably attributable to it's modest efficacy profile. Incidentally, if it was more "powerful", there would be a greater likelihood of increased side effects on other functions or organs.

As far as "preponderance of evidence" is concerned...when the pharma industry begins to show some interest, or supplement sales skyrocket, or pharma grade clinical results are produced, or more influential institutions get behind the science with considerable capital (Roskamp/Mullen is only a start, and the follow through, as yet, has been very disappointing), then I may buy your argument. Until then, your preponderance position is simply preposterous.